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ABSTRACT
Objective  To assess the efﬁ  cacy and safety of 
golimumab + methotrexate (MTX) in Japanese patients 
with active rheumatoid arthritis (RA).
Methods  269 Japanese patients with active RA despite 
treatment with MTX were randomised (1:1:1) to placebo 
+ MTX (Group 1), golimumab 50 mg + MTX (Group 2) 
or golimumab 100 mg + MTX (Group 3). Subcutaneous 
golimumab/placebo was injected every 4 weeks; stable 
doses of oral MTX (6–8 mg/week) were continued. 
Patients were allowed to enter early escape (Group 1 
added golimumab 50 mg, Group 2 increased golimumab 
to 100 mg, Group 3 continued golimumab 100 mg) 
based on swollen/tender joint counts at week 14. The 
primary study endpoint was achievement of at least 20% 
improvement in the American College of Rheumatology 
(ACR20) response criteria at week 14. To control for 
multiplicity of testing, treatment group comparisons were 
ﬁ  rst made between combined Groups 2 and 3 versus 
Group 1, followed by comparisons of Group 2 and Group 3 
versus Group 1.
Results  The proportion of patients with an ACR20 
response at week 14 was signiﬁ  cantly higher in 
combined Groups 2 and 3 (73.4%, 127/173) and in each 
of Group 2 (72.1%, 62/86) and Group 3 (74.7%, 65/87) 
compared with Group 1 (27.3%, 24/88; p<0.0001 for 
all comparisons). Golimumab + MTX also elicited a 
signiﬁ  cantly better response than placebo + MTX in 
other efﬁ  cacy parameters, including disease activity 
score (DAS28) response/remission and radiographic 
assessments. During the 16-week ﬁ  xed treatment 
regimen study period, 72.7%, 75.6% and 78.2% of 
patients had adverse events and 1.1%, 1.2% and 
2.3% had serious adverse events in Groups 1, 2 and 3, 
respectively.
Conclusion  In Japanese patients with active RA despite 
MTX therapy, golimumab + MTX was signiﬁ  cantly more 
effective than MTX monotherapy in reducing RA signs/
symptoms and limiting radiographic progression with no 
unexpected safety concerns.
INTRODUCTION
Rheumatoid arthritis (RA) is a chronic autoimmune 
inﬂ   ammatory disease mediated by overproduc-
tion of cytokines such as tumour necrosis factor 
α (TNF).1 2 Golimumab, a newer human anti-TNF 
monoclonal antibody that binds with high afﬁ  n-
ity and speciﬁ  city to soluble and transmembrane 
TNF,3 antagonises the effects of TNF.1 Golimumab 
+ methotrexate (MTX) has demonstrated statisti-
cally signiﬁ  cant efﬁ  cacy versus MTX monotherapy 
in MTX-naïve patients with RA4 and in patients 
with active RA despite prior MTX therapy.5 6
In a phase 1 study of healthy age- and dose-
matched Japanese men (n=24) and Caucasian sub-
jects (n=27), the pharmacokinetics of golimumab 
were comparable between ethnic groups.7 A phase 
2/3 study was conducted to examine the efﬁ  cacy 
and safety of golimumab in Japanese patients with 
active RA despite MTX therapy.
METHODS
Patients
Eligible patients were adults (age 20–75 years) with 
RA diagnosed according to the American College of 
Rheumatology (ACR) 1987 revised criteria,8 with 
disease duration of ≥3 months who had received 
≥6 mg/week oral MTX for RA for ≥3 months before 
study agent initiation. Stable MTX doses (6–8 mg/
week) were required for ≥4 weeks before the start 
of the study. Patients had to have active RA (≥4/66 
swollen joints and ≥4/68 tender joints at screening/
baseline) and had to meet at least two of the follow-
ing criteria at screening/baseline: (1) C-reactive pro-
tein (CRP) >1.5 mg/dl or erythrocyte sedimentation 
rate (ESR) by the Westergren method of >28 mm/h, 
(2) morning stiffness lasting ≥30 min, (3) radio-
graphic evidence of bone erosion, or (4) anti-cyclic 
citrullinated peptide antibody-positive or rheuma-
toid factor-positive. Eligible patients also met pre-
speciﬁ  ed concomitant medication and tuberculosis 
screening criteria (see online supplement).
Study design
This multicentre phase 2/3 study (ClinicalTrials.
gov NCT00727987) had a 24-week, randomised, 
double-blind, placebo-controlled phase followed 
by an open-label extension continuing through 3 
years. This report presents clinical data through 
week 24. The study was conducted according to 
Declaration of Helsinki and Good Clinical Practice 
guidelines. The protocol was reviewed and 
approved by all institutional review boards. All 
patients provided written informed consent prior 
to study participation.
Eligible patients were randomly (1:1:1) assigned 
to receive placebo injection + oral MTX (Group 1), 
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variables, treatment group differences were assessed using anal-
ysis of covariance (ANCOVA) with treatment as a factor and 
baseline value as a covariate or analysis of variance (ANOVA) 
with treatment as a factor. For comparisons of changes in vdH-S 
score, ANCOVA based on least squares mean and accompany-
ing two-sided 95% conﬁ  dence intervals was detailed a priori, 
and ANOVA based on van der Waerden normal scores was con-
ducted post hoc for ease of comparison with the radiographic 
results of the GO-FORWARD study.16 ANCOVA results are pre-
sented herein. A cumulative probability plot depicting changes 
in the vdH-S score (shown in ascending order of magnitude with 
smaller changes indicating greater inhibition of disease progres-
sion) was also constructed. The proportions of patients with no 
change in the vdH-S score and with changes in excess of the 
smallest detectable change (SDC=3.23) were also determined and 
compared among treatment groups with a χ2 test. Agreement 
between the two primary readers for vdH-S scores was assessed 
by determination of intraclass correlation coefﬁ  cients (ICCs).
RESULTS
Patient disposition and baseline characteristics
Data for this report were collected beginning in May 2008 and 
the week 24 database was locked in September 2009. Two 
hundred and sixty-nine patients were enrolled at 89 investiga-
tional sites in Japan and randomised to Group 1 (n=90), Group 
2 (n=89) or Group 3 (n=90); 261 patients received at least one 
study treatment (n=88, 86 and 87 in Groups 1, 2 and 3, respec-
tively). Eight patients discontinued the study before receiving 
study treatment. Similar proportions of treated patients com-
pleted subcutaneous administration of the study agent through 
the week 24 visit in Group 1 (95.5%), Group 2 (94.2%) and 
Group 3 (92.0%) (ﬁ  gure 1). 
The overall mean (SD) baseline vdH-S score was 55.1 (58.1) 
and duration of RA was 8.5 (7.9) years. Baseline demographic 
and disease characteristics were generally consistent across the 
three treatment groups, with the exception of shorter mean 
disease duration (8.1 years) and lower mean baseline CRP level 
(1.5 mg/dl) in Group 3 compared with Group 1 (8.7 years and 
2.2 mg/dl, respectively) and Group 2 (8.8 years and 1.9 mg/dl, 
respectively) (table 1).
Efﬁ  cacy results
ACR response
Analysis of the primary endpoint (ie, ACR20 response at week 14) 
demonstrated a signiﬁ  cant difference between combined Groups 
2 and 3 (73.4%, 127/173) and Group 1 (27.3%, 24/88) (p<0.0001; 
table 2). Signiﬁ  cantly higher ACR20 response rates were also 
observed in Group 2 (72.1%, 62/86; p<0.0001) and Group 3 
(74.7%, 65/87; p<0.0001) versus Group 1. Consistent ﬁ  ndings 
were observed for ACR50 and ACR70 responses (table 2).
Differences in ACR response between golimumab + MTX and 
placebo + MTX were evident as early as week 4 and maintained 
through week 24 (ﬁ  gure 2). Patients in Group 1 who crossed 
over to golimumab 50 mg + MTX and patients in Group 2 who 
increased the golimumab dose from 50 mg to 100 mg + MTX 
appeared to demonstrate clinical beneﬁ  t following the change in 
study treatment (ﬁ  gure 2).
Other clinical measures of RA and physical function
Statistical comparisons of combined Groups 2 and 3 versus Group 
1, as well as for Group 2 versus Group 1 and Group 3 versus Group 
1, were signiﬁ   cant for supportive clinical efﬁ  cacy  parameters 
including ACR-N Index of Improvement, DAS28(ESR) response 
and DAS28(ESR) remission (table 2). At week 14, a signiﬁ  cantly 
golimumab 50 mg injection + oral MTX (Group 2) or golimumab 
100 mg injection + oral MTX (Group 3). Golimumab and placebo 
were supplied as sterile liquid (Janssen Biotech Inc, Horsham, 
Pennsylvania, USA) for subcutaneous injection at week 0 and 
every 4 weeks to week 24. MTX doses were not adjusted unless 
dose reduction was required because of MTX toxicity.
At week 16, patients with <20% improvement from baseline 
in tender and swollen joint counts at week 14 could enter dou-
ble-blind early escape (EE). Group 1 added golimumab 50 mg, 
Group 2 increased the golimumab dose to 100 mg and Group 3 
continued golimumab 100 mg.
Study endpoints
The primary study endpoint was response according to achieve-
ment of at least 20% improvement in the ACR response criteria9 at 
week 14, prior to any change in treatment at week 16. Additional 
efﬁ   cacy assessments included ACR50 and ACR70 responses, 
ACR-N Index of Improvement10 and Disease Activity Score using 
28 joints and ESR (DAS28(ESR)). DAS28(ESR) response (moder-
ate and good ratings) and remission (DAS28(ESR) score <2.6) 
were also determined.11 12 Physical function was assessed using 
the disability index of the Health Assessment Questionnaire 
(HAQ-DI).13 All efﬁ  cacy assessments were conducted at baseline 
(week 0) and at weeks 4, 8, 12, 14, 16, 20 and 24.
Hand and feet x-rays were obtained before administration of 
study agent at weeks 0 and 24 or upon premature discontinua-
tion. They were scored by the BioClinica Corporation (Newtown, 
Pennsylvania, USA) using the Sharp score as modiﬁ  ed by van 
der Heijde and colleagues (vdH-S).14 Two primary readers who 
were blinded to patient identity, treatment group assignment and 
x-ray time point read the x-rays. If the readers’ scores differed by 
≥10 points or data were unavailable for one reader, a third reader 
evaluated the x-rays. In the former case, the reader score that dif-
fered the least from the adjudicator’s score was used.
In a post hoc analysis, the relationship between efﬁ  cacy and 
serum study agent concentrations was examined, whereby ACR 
response rates were categorised by serum golimumab concen-
tration quartiles: <0.55 μg/ml (n=46), ≥0.55–<0.98 μg/ml (n=44), 
≥0.98–<1.55 μg/ml (n=48) and ≥1.55 μg/ml (n=46).
Safety assessments included adverse events (AEs) and routine 
laboratory analyses. Serum golimumab concentrations and anti-
bodies to golimumab were determined.15
Statistical analyses
Efﬁ  cacy and pharmacology parameters were primarily assessed 
according to a modiﬁ   ed intent-to-treat approach in which 
patients who did not meet the study eligibility criteria, did not 
receive study treatment and/or had no efﬁ  cacy- or pharmacol-
ogy-related data following randomisation were excluded from 
the full analysis patient population. Safety analyses included all 
randomised treated patients. Further details of prespeciﬁ  ed data 
handling rules and sample size calculations are provided in the 
online supplement.
Treatment group differences in dichotomous variables were 
assessed with a χ2 test. Type I error at the 0.05 level of signiﬁ  -
cance was preserved with a hierarchical approach to control for 
multiplicity when testing, wherein the comparison between 
combined Groups 2 and 3 versus Group 1 was made ﬁ  rst. If this 
difference was signiﬁ  cant, pairwise comparisons between Group 
2 versus Group 1 and Group 3 versus Group 1 were performed. 
In data summaries that did not present patients who entered EE 
separately, such patients were grouped by randomised group and 
had week 24 data replaced with week 16 data. For continuous 
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Improvements in the HAQ-DI score at week 24, as well as the 
proportions of patients achieving a HAQ score <0.5, were also 
signiﬁ  cantly greater among patients who received golimumab + 
MTX versus placebo + MTX (table 2).
greater median improvement in the HAQ-DI score was observed 
in patients who received golimumab + MTX (median of 0.25 
for combined Groups 2 and 3, Group 2 and Group 3) versus 
placebo + MTX (median 0.13; p<0.0001 for all comparisons). 
Table 1  Baseline patient and disease characteristics: full analysis patient population*
  Group 1: Placebo+MTX Group 2: Golimumab 50 mg+MTX Group 3: Golimumab 100 mg+MTX Combined Groups 2 and 3
Number of patients 88 86 87 173
Female patients, n (%) 73 (83.0%) 73 (84.9%) 78 (89.7%) 151 (87.3%)
Age (years) 51.1 (11.6), 51.0 [24, 73] 50.4 (9.9), 52.0 [25, 72] 50.0 (12.2), 52.0 [21, 73] 50.2 (11.1), 52.0 [21, 73]
Average duration of RA (years) 8.7 (8.2), 6.4 [0.3, 46.1] 8.8 (8.8), 6.4 [0.4, 36.8] 8.1 (6.5), 6.4 [0.5, 32.4] 8.4 (7.7), 6.4 [0.4, 36.8]
<1 year, n (%) 9 (10.2%) 8 (9.3%) 5 (5.7%) 13 (7.5%)
≥1–<3 years, n (%) 20 (22.7%) 20 (23.3%) 15 (17.2%) 35 (20.2%)
≥3–<5 years, n (%) 13 (14.8%) 10 (11.6%) 14 (16.1%) 24 (13.9%)
≥5–<10 years, n (%) 16 (18.2%) 21 (24.4%) 26 (29.9%) 47 (27.2%)
≥10 years, n (%) 30 (34.1%) 27 (31.4%) 27 (31.0%) 54 (31.2%)
Swollen joint count (0–66) 11.4 (6.58), 9.0 [4, 36] 11.8 (6.72), 10.0 [4, 33] 11.5 (6.58), 9.0 [4, 32] 11.6 (6.63), 9.0 [4, 33]
Tender joint count (0–68) 13.2 (7.83), 11.0 [4, 45] 13.1 (8.38), 11.0 [4, 40] 12.9 (7.64), 11.0 [4, 39] 13.0 (7.99), 11.0 [4, 40]
Patient’s assessment of pain 
  (VAS 0–100 mm)
52.2 (22.86), 51.5 [2, 100] 49.5 (23.80), 48.0 [3, 100] 47.0 (23.88), 47.0 [6, 100] 48.2 (23.80), 48.0 [3, 100]
Patient’s global assessment of disease 
  activity (VAS 0–100 mm)
50.7 (22.63), 48.0 [2, 100] 46.1 (23.07), 47.5 [1, 100] 45.3 (22.90), 48.0 [4, 100] 45.7 (22.92), 48.0 [1, 100]
Physician’s global assessment of 
  disease activity (VAS 0–100 mm)
54.4 (17.97), 57.0 [22, 96] 58.0 (18.77), 59.0 [12, 91] 54.5 (17.81), 57.0 [14, 87] 56.2 (18.32), 58.0 [12, 91]
HAQ-DI (0–3) 1.0 (0.68), 0.9 [0.0, 2.8] 1.0 (0.61), 1.0 [0.0, 2.4] 0.9 (0.59), 0.9 [0.0, 3.0] 0.9 (0.60), 0.9 [0.0, 3.0]
CRP (mg/dl) 2.2 (2.44), 1.3 [0.0, 15.5] 1.9 (2.63), 0.9 [0.0, 13.9] 1.5 (1.68), 1.0 [0.0, 8.2] 1.7 (2.21), 0.9 [0.0, 13.9]
DAS (ESR) 5.6 (0.99), 5.6 [2.8, 8.0] 5.5 (1.18), 5.6 [3.1, 8.8] 5.5 (0.97), 5.4 [3.5, 8.2] 5.5 (1.07), 5.5 [3.1, 8.8]
vdH-S score
  Total score 54.2 (62.9), 32.3 [0.0, 289.2] 58.0 (62.4), 35.0 [0.0, 300.5] 53.2 (48.4), 43.0 [0.0, 215.0] 55.6 (55.7), 37.5 [0.0, 300.5]
  JSN score 23.4 (27.4), 13.5 [0.0, 128.0] 25.9 (29.4), 14.5 [0.0, 127.0] 23.9 (24.5), 16.5 [0.0, 99.0] 24.9 (27.0), 16.0 [0.0, 127.0]
 Erosion  score 30.8 (37.1), 17.8 [0.0, 190.0] 32.1 (34.7), 20.8 [0.0, 185.0] 29.3 (26.3), 21.0 [0.0, 116.0] 30.7 (30.7), 21.0 [0.0, 185.0]
Values are mean (SD), median [range] unless otherwise speciﬁ  ed.
*The full analysis patient population excluded patients who did not meet the study eligibility criteria, who did not receive study treatment and/or who had no efﬁ  cacy data following 
randomisation.
CRP, C-reactive protein; DAS 28 (ESR), disease activity score using 28-joint count and erythrocyte sedimentation rate; HAQ-DI, Health Assessment Questionnaire Disability Index; JSN, 
joint space narrowing; MTX, methotrexate; RA, rheumatoid arthritis; VAS, visual analogue scale; vdH-S, van der Heijde-modiﬁ  ed Sharp score.
Figure 1  Patient disposition through week 24; randomised patients. Note that ‘worsening of rheumatoid arthritis’ is included in ‘unsatisfactory 
therapeutic response’ and not as an AE. AE, adverse event; EE, early escape; pts, patients.
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inhibition of radiographic progression was greater in patients 
treated with golimumab + MTX (Group 2 and Group 3) than in 
those given placebo + MTX (Group 1). 
Signiﬁ   cantly greater proportions of patients in combined 
Groups 2 and 3 (64.7%, p=0.0217) and Group 3 (70.1%, p=0.0066) 
did not have an increase in the total vdH-S score (ie, change from 
baseline to week 24 <0) compared with Group 1. The proportions 
of patients with a change in the total vdH-S score from baseline 
to week 24 greater than the SDC (3.23) were also signiﬁ  cantly 
lower in combined Groups 2 and 3 (11.0%, p=0.0216) and Group 
3 (5.7%, p=0.0023) compared with Group 1 (table 2).
Golimumab pharmacokinetics and antibodies to golimumab
Median serum golimumab concentrations were approximately 
dose proportional and appeared to have reached steady state by 
week 14. Median serum golimumab concentrations at weeks 12 
and 16 were 0.72 and 0.73 μg/ml, respectively, for Group 2 and 
1.28 and 1.16 μg/ml, respectively, for Group 3. These steady state 
concentrations were maintained at week 24. In Group 2, serum 
golimumab concentrations in patients who met the EE criteria 
were approximately 45–82% of those in Group 2 patients who 
did not meet the EE criteria (data not shown).
In an analysis of week 24 ACR response by week 24 goli-
mumab concentration quartiles, the lowest response rates 
occurred in patients with serum golimumab concentrations 
<0.55 μg/ml, followed by concentrations ≥0.55–<0.98 μg/ml 
(ﬁ  gure 3). No patient developed antibodies to golimumab.
Adverse events
AEs reported at week 16 (ﬁ  xed treatment regimen study period) 
and week 24 are summarised in table 3. By week 16, 72.7% 
(64/88), 75.6% (65/86) and 78.2% (68/87) of patients in Groups 
1, 2 and 3, respectively, had AEs. Infections were the most com-
mon AEs in Group 1 (35/88, 39.8%), Group 2 (33/86, 38.4%) 
and Group 3 (29/87, 33.3%) through week 16 and were also the 
most common AEs at week 24 (table 3).
Serious AEs were relatively uncommon through week 16, occur-
ring in one patient (1.1%) in Group 1 (intervertebral disc protru-
sion), one patient (1.2%) in Group 2 (ileus) and two patients (2.3%) 
Radiographic progression
The primary readers exhibited good agreement with regard to 
vdH-S scores, with ICCs of 0.98 for baseline scores, 0.98 for 
week 24 scores and 0.80 for the change from baseline to week 
24 in vdH-S scores.
Signiﬁ  cantly less radiographic progression from baseline to 
week 24 was observed in patients who received golimumab + 
MTX (median changes in total vdH-S score of 0.00 (p=0.0009) 
for combined Groups 2 and 3, 0.00 (p=0.0203) for Group 2 and 
0.00 (p=0.0006) for Group 3) versus placebo + MTX (median 
change 0.25). Treatment group differences in the total vdH-S 
score were largely attributable to signiﬁ  cantly less change in the 
erosion score with golimumab + MTX therapy. As shown in 
the cumulative probability plot shown in ﬁ  gure 1 in the online 
supplement, changes in vdH-S scores were smaller and thus 
Figure 2  (A) American College of Rheumatology 20% (ACR20), 
(B) 50% (ACR50) and (C) 70% (ACR70) improvement from baseline 
through week 24. Note that patients who met the early escape criteria 
at week 16 and crossed over to golimumab 50 mg or dose escalated 
from golimumab 50 mg to 100 mg are shown with an open triangle and 
closed circle, respectively. For the 28 patients in the placebo + MTX 
group and the nine patients in the golimumab 50 mg + MTX group who 
met the early escape criteria, week 20 and 24 data were imputed using 
last observation carried forward methodology, as were other missing 
data. As such, 88 patients in the placebo + MTX group and 86 patients 
in the golimumab 50 mg + MTX group were included in these data 
displays. MTX, methotrexate.
Figure 3  Proportions of patients achieving at least 20%, 50% and 70% 
improvement in the American College of Rheumatology (ACR20, ACR50, 
ACR70) response criteria by serum golimumab concentration quartiles 
(µg/ml) at week 24. The results are from a post hoc analysis of ACR 
responders in the combined Group 2 (golimumab 50 mg + MTX) and 
Group 3 (golimumab 100 mg + MTX). MTX, methotrexate.
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the same time period, yielding no signiﬁ  cant differences between 
golimumab + MTX and placebo + MTX.5 16 Minimal radio-
graphic progression was probably related to minimal baseline 
active inﬂ  ammation (median CRP 0.8–1.0 mg/dl).5 16 In a separate 
study of golimumab, MTX-naïve patients with RA had higher 
baseline CRP levels (median 1.3–1.4 mg/dl), greater radiographic 
progression than in the GO-FORWARD study despite less base-
line radiographic damage and signiﬁ  cantly less radiographic pro-
gression at week 28 with golimumab + MTX versus placebo + 
MTX.5 16 Thus, CRP is likely to be a more important predictor 
of radiographic progression than the baseline radiographic score 
since radiographic progression is less likely if there is no active 
inﬂ  ammation, regardless of the amount of baseline radiographic 
damage.16 The CRP concentration has also been shown to predict 
ACR20 response.17 In this context, the participants in the cur-
rent study had an intermediate amount of active inﬂ  ammation 
at baseline (median CRP 0.9–1.3 mg/dl) and also demonstrated 
signiﬁ  cantly less radiographic progression at week 24 with goli-
mumab + MTX compared with placebo + MTX. In evaluating 
the radiographic data, it is important to note that the statistically 
signiﬁ  cant differences between the groups are driven by a subset 
of patients who progress more rapidly than the overall popula-
tion, and it is in those patients that the treatment effect becomes 
clinically relevant.
Of note, the MTX dose used in this trial, while consistent with 
that approved in Japan at the time the trial was planned, was 
suboptimal (6–8 mg/week) in the context of customary doses 
elsewhere18 and as used in the GO-FORWARD study (15–25 
mg/week).16 Evaluation of the efﬁ  cacy and safety of MTX doses 
>8 mg/week in Japanese patients with RA has yielded a favour-
able beneﬁ  t/risk proﬁ  le19 and approved dosing is now extended 
to up to 16 mg/week. It would therefore be prudent to reassess 
the responses to golimumab as approved MTX doses in Japan are 
harmonised with those approved in North America and Europe 
for RA. These suboptimal MTX doses may explain the higher 
ACR20 response rates observed in the current golimumab trial 
(~70%) compared with previously conducted trials of golimumab 
in RA (~60%) in which more robust ongoing MTX treatment 
regimens (10–15 mg/week) could have resulted in less room for 
improvement from baseline.4 5 It is noteworthy that, when assess-
ing response according to the more stringent ACR50 and ACR70 
response criteria, the background MTX dose does not appear to 
affect the clinical response.4 5 Similar reasoning may be applied to 
explain the highly signiﬁ  cant difference in radiographic progres-
sion observed between placebo + MTX and golimumab + MTX 
despite only an intermediary level of baseline inﬂ  ammation com-
pared with previously conducted trials of golimumab.4 5 16 Finally, 
more patients met the EE criteria in the golimumab 50 mg + MTX 
group (Group 2) than in the golimumab 100 mg + MTX group 
(Group 3), indicating the potential for a dose response.
In interpreting the efﬁ  cacy ﬁ  ndings of this study, it is impor-
tant to bear in mind that patients could enter this study based on 
measures of disease activity generally considered to be subjec-
tive in nature (ie, tender and swollen joint counts and morning 
stiffness) or reported from each trial site (ESR) without conﬁ  r-
mation by centrally determined parameters such as CRP or ero-
sions. This could have resulted in study enrolment of patients 
with relatively inactive disease.
Golimumab was generally well tolerated with no unexpected 
safety issues observed in Japanese patients with RA. By week 24, 
approximately 10% of all patients treated with golimumab + MTX 
had an injection site reaction. A variety of dermatological adverse 
effects, including injection site reactions and dermatitis, have been 
reported for TNF antagonists such as adalimumab, etanercept and 
in Group 3 (herpes zoster/tendon rupture and aortic dissection). 
Two additional patients had serious AEs between weeks 16–24, 
including bone neoplasm (thoracic vertebra tumour (haemangoen-
dothelioma) with ‘borderline’ or low malignancy potential) in 
Group 2 and humeral fracture/cruciate ligament injury in Group 3, 
yielding a total of ﬁ  ve (2.5%) patients treated with golimumab + 
MTX with serious AEs through week 24. No deaths or malignan-
cies were reported.
In addition, by week 16, one (1.1%), three (3.5%) and six (6.9%) 
patients in Groups 1, 2 and 3, respectively, discontinued the study 
agent because of an AE. By week 24, 11 (5.5%) of the 201 patients 
treated with golimumab + MTX had discontinued golimumab due 
to AEs; these included infection (n=2), skin disorders (n=2), liver 
function abnormality (n=2), injury (n=2), bone neoplasm (n=1), 
aortic dissection (n=1), gastrointestinal disorder (n=1) and elevated 
blood pressure (n=1 in combination with skin disorder).
As noted, infection was the most common system organ class 
of AEs, occurring in 35 (39.8%), 33 (38.4%) and 29 (33.3%) 
patients in Groups 1, 2 and 3, respectively, up to week 16. By 
week 24, 74 (36.8%) patients treated with golimumab + MTX 
had an infection, most commonly rhinopharyngitis (19.4%, 
39/201), gastroenteritis (3.5%, 7/201) and pharyngitis (3.0%, 
6/201). No patient developed tuberculosis.
Injection site reactions were reported in six (6.8%), seven 
(8.1%) and nine (10.3%) patients in Groups 1, 2 and 3, respec-
tively, up to week 16. By week 24, 10.4% (21/201) of all patients 
treated with golimumab + MTX had an injection site reaction. 
Erythema at the injection site was the most common of these 
AEs. All injection site reactions were considered mild and none 
required cessation of the study agent. No cases of anaphylactic 
reaction or serum sickness-like reactions were observed.
DISCUSSION
This study evaluated the efﬁ  cacy of golimumab 50 mg and 100 
mg administered subcutaneously every 4 weeks in combination 
with MTX (6–8 mg/week) versus MTX (6–8 mg/week) mono-
therapy in Japanese patients with active RA despite MTX ther-
apy. A signiﬁ  cantly higher proportion of patients randomised 
to golimumab 50 mg or 100 mg + MTX (combined Groups 
2 and 3) achieved an ACR20 response at week 14 than those 
receiving MTX monotherapy (73.4% versus 27.3%; p<0.0001). 
Signiﬁ  cantly higher ACR20 response rates were also observed 
for the individual golimumab dose groups. While the primary 
endpoint at week 14 did not coincide with trough golimumab 
concentrations, ACR20 response rates at the time of trough 
concentrations (week 16) were comparable to those observed 
at week 14 (ie, 71.7% and 29.5%, respectively, in combined 
Groups 2 and 3 and Group 1, respectively; data not shown).
These primary endpoint results were consistent with the 
results of the GO-FORWARD study, a large phase 3 multi-
centre trial of golimumab encompassing a similar design (pri-
mary endpoint at week 14 and treatment change due to EE from 
week 16 onwards) and a comparable population of patients 
with RA (approximately 15% of whom were Asian; data on 
ﬁ  le, Centocor Research & Development) with an inadequate 
response to MTX.5 Consistency between our ﬁ  ndings and those 
of the GO-FORWARD study was also observed for improve-
ments in HAQ-DI at week 24.5
Signiﬁ   cantly less radiographic progression was observed at 
week 24 with golimumab + MTX than with placebo + MTX, and 
ﬁ  ndings of a post hoc ANOVA analysis of vdH-S scores based 
on the van der Waerden normal scores were consistent (data not 
shown). In the GO-FORWARD study, however, minimal radio-
graphic progression was observed in all treatment groups during 
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inﬂ  iximab,20 as well as for anakinra, a recombinant human form 
of interleukin-1 receptor antagonist.21 These dermatological com-
plications typically are well-tolerated, respond to antihistamines 
and do not necessitate treatment discontinuation.
The incidences of serious AEs, serious infections and malig-
nancies during the ﬁ  xed treatment regimen period were low and 
similar with placebo + MTX (1.1%, 0.0% and 0.0%, respec-
tively) and combined golimumab + MTX (1.7%, 0.6% and 0.0%, 
respectively). These ﬁ  ndings indicate a safety proﬁ  le similar to   
placebo + MTX (2.3%, 0.8% and 0.0%, respectively) and goli-
mumab + MTX (7.3%, 3.9% and 1.1%, respectively) at week 16 
in the GO-FORWARD study.5 However, these safety ﬁ  ndings 
must be interpreted with caution given the relatively small num-
ber of patients evaluated, the lack of power to detect treatment 
group differences in individual safety events and the relatively 
short follow-up period. No patients died and no cases of tuber-
culosis were documented during the 24-week study period.
Taken together, the efﬁ  cacy and safety ﬁ  ndings presented here 
indicate that golimumab 50 mg + MTX and golimumab 100 mg + 
MTX were at least as safe and effective in these Japanese patients 
with active RA despite MTX therapy as they were observed to 
be when administered to patients with RA who also had an inad-
equate response to MTX in the GO-FORWARD study.5
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